This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | MicrobiomeTrials
← Back to trials NCT04750928
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2021-11-29Est. Completion: 2028-12-31
Enrollment target: 55 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Low Grade Astrocytoma Low Grade Glioma Metastatic Low Grade Astrocytoma Metastatic Low Grade Glioma WHO Grade 1 Glioma WHO Grade 2 Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincr…
Birmingham, United States Est. completion Dec 31, 2030
Neurofibromatosis Type 1
Neurofibromatosis type 1 (NF1), a genetic disorder, results from NF1 gene mutations with nearly complete penetrance (1).…
Al Mansurah, Egypt
Est. completion Sep 30, 2026
Low Grade Glioma (LGG) of Brain With BRAF Aberration High Grade Glioma (HGG) of the Brain With BRAF Aberration Low Grade Glioma of Brain With Neurofibromatosis Type 1
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabr…
Phoenix, United States Est. completion Oct 1, 2026